What lipodystrophies teach us about the metabolic syndrome

Jake P. Mann, David B. Savage


Lipodystrophies are the result of a range of inherited and acquired causes, but all are characterized by perturbations in white adipose tissue function and, in many instances, its mass or distribution. Though patients are often nonobese, they typically manifest a severe form of the metabolic syndrome, highlighting the importance of white fat in the “safe” storage of surplus energy. Understanding the molecular pathophysiology of congenital lipodystrophies has yielded useful insights into the biology of adipocytes and informed therapeutic strategies. More recently, genome-wide association studies focused on insulin resistance have linked common variants to genes implicated in adipose biology and suggested that subtle forms of lipodystrophy contribute to cardiometabolic disease risk at a population level. These observations underpin the use of aligned treatment strategies in insulin-resistant obese and lipodystrophic patients, the major goal being to alleviate the energetic burden on adipose tissue.
What lipodystrophies teach us about the metabolic syndrome

Jake P. Mann and David B. Savage

Metabolic Research Laboratories, Wellcome Trust–MRC Institute of Metabolic Science, University of Cambridge, Cambridge, United Kingdom.

Lipodystrophies are the result of a range of inherited and acquired causes, but all are characterized by perturbations in white adipose tissue function and, in many instances, its mass or distribution. Though patients are often nonobese, they typically manifest a severe form of the metabolic syndrome, highlighting the importance of white fat in the “safe” storage of surplus energy. Understanding the molecular pathophysiology of congenital lipodystrophies has yielded useful insights into the biology of adipocytes and informed therapeutic strategies. More recently, genome-wide association studies focused on insulin resistance have linked common variants to genes implicated in adipose biology and suggested that subtle forms of lipodystrophy contribute to cardiometabolic disease risk at a population level. These observations underpin the use of aligned treatment strategies in insulin-resistant obese and lipodystrophic patients, the major goal being to alleviate the energetic burden on adipose tissue.

Introduction

Lipodystrophies are a heterogeneous group of conditions characterized by a lack of, and/or dysfunctional, white adipose tissue. They may be genetic (inherited) or acquired in origin and localized, partial, or generalized in distribution; however, despite the etiological heterogeneity, other than localized forms and most cases of Barraquer-Simons acquired partial lipodystrophy, they almost all cause insulin resistance, nonalcoholic fatty liver disease (NAFLD), and dyslipidemia (characterized by high triglyceride and low HDL cholesterol concentrations) (1). Therefore, even though patients are often (though not always) nonobese or lean, lipodystrophies mirror the metabolic syndrome associated with obesity.

Although lipodystrophies are relatively rare, studying these patients has advanced understanding of adipose biology and the pathophysiology of the metabolic syndrome. They act as very informative models of inadequate adipose storage capacity in the face of excess energy intake, resulting in ectopic fat accumulation and insulin resistance. Accumulating evidence suggests that similar mechanisms of adipose overload are responsible for insulin resistance in patients with obesity (2, 3), and therefore treatment is conceptually similar for lipodystrophies and obesity; for example, limited data in patients with familial partial lipodystrophy suggest that bariatric surgery is highly effective in alleviating the metabolic consequences of lipodystrophy (4–6), as has been widely reported in obesity (7).

White adipose tissue is the primary site for physiological energy storage in humans (ref. 8 and Figure 1). Surplus energy can only really be stored as glycogen (carbohydrate) or triglyceride (neutral lipid), and the latter represents a more concentrated/energy-dense (9 vs. 4 kcal/g) and “lighter” reserve, so it is not surprising that a lean adult human stores approximately 100-fold more energy as triglyceride compared with glycogen (9). In healthy adult humans almost all triglyceride is stored within white adipose tissue, which regulates the uptake of substrates (e.g., glucose and nonesterified fatty acids), the synthesis of neutral lipid for storage, and the release of stored triglycerides through lipolysis. These processes are under nervous, hormonal, and nutritional regulation to facilitate homeostatic energy balance but can be perturbed by chronic overnutrition (resulting in obesity) or inherited disorders of white adipose tissue (lipodystrophies). Adipocytes signal the status of their energy reserves by secreting leptin, which in turn acts centrally to influence energy balance and reproductive capacity. They also secrete a host of other proteins (collectively known as adipokines) with a range of purported functions (10, 11). Clearly, in addition to perturbing energy storage, lipodystrophies may well alter adipokine secretion and/or interactions with stromovascular cells present in adipose tissue. These changes could also contribute to the physiological changes associated with lipodystrophy but have, for the most part, not been extensively studied and so are not considered in detail here.

White fat is distributed in several characteristic sites (or “depots”; Figure 1), which differ substantially between humans and mice. For example, humans do not have a large gonadal fat pad, which is a commonly isolated and studied fat depot in mice. Importantly, adipogenesis, lipogenesis, and lipolysis vary in their physiological regulation in these depots (12–14). For example, human studies have suggested that lipolysis is higher in visceral (intra-abdominal) than in subcutaneous white adipose tissue (15). In this Review, we highlight examples of inherited lipodystrophies where selective loss of gluteofemoral fat can recapitulate features of the metabolic syndrome, even if upper body fat depots are unaffected. In other cases, where fat loss is restricted to the face, upper trunk, and arms, patients do not typically manifest metabolic disease.
Insights from inherited lipodystrophy syndromes with well-defined mechanisms

Clearly defined monogenic diseases can provide unique insights into the biological function of specific genes and the proteins they encode, somewhat akin to observations made in knockout or hypomorphic mouse models. In several cases (for example, PPARG, encoding peroxisome proliferator–activated receptor γ), the link between specific genes implicated in causing lipodystrophy and adipose dysfunction is clear, whereas in others (such as LMNA, encoding lamin A/C), the mechanism is yet to be fully understood. Below, we briefly review selected situations in which the link between particular genes and adipose dysfunction is relatively clear; these include examples involving genes implicated in the transcriptional regulation of adipogenesis, triglyceride synthesis, lipid droplet morphology, and lipolysis (Figure 2).

**PPARG.** Peroxisome proliferator–activated receptors (PPARs) α, δ, and γ were identified nearly 30 years ago (16). They all have a DNA-binding domain (DBD) as well as a ligand-binding domain (LBD) that is believed to bind, somewhat promiscuously, a range of putative fatty acid ligands (17–20). Seminal in vitro studies undertaken in the 1990s established that PPARγ is essential for adipocyte differentiation (21–24), and it is now generally considered to be the “master regulator” of both adipogenesis, the process through which fibroblast-like precursors are converted into mature adipocytes, and mature adipocyte function (21, 23). It is therefore not surprising that PPARγ mutations cause lipodystrophy, but why these mutations are usually associated with a stereotypical pattern of partial lipodystrophy remains an unresolved puzzle.

Heterozygous, dominant-negative mutations in PPARG are associated with autosomal dominant familial partial lipodystrophy type 3 (FPLD3). Several case studies have reported patients with severe insulin resistance, dyslipidemia in which hypertriglyceridemia appears to be exquisitely sensitive to high fat intake (25), type 2 diabetes mellitus, reduced subcutaneous gluteofemoral and leg fat, and hypertension (26–35). Affected women frequently manifest features of polycystic ovary syndrome (26, 36, 37) and premature-onset cardiovascular disease (26), and cirrhosis has been reported (28, 38). The majority of patients with FPLD3 are diagnosed with lipodystrophy in early adulthood, though affected children have been identified through family screening studies (35) and men typically present later than women.

Heterozygous autosomal dominant mutations in either the DBD or LBD of PPARγ have been associated with lipodystrophy (27, 39), though debate continues about whether or not these mutations truly manifest dominant-negative properties (40). LBD variants can bind to DNA response elements but manifest impaired transcriptional responses to agonists or coactivators (35). DBD mutants impair DNA binding, but they can also inhibit wild-type function, possibly via sequestration of coactivators (36). Heterozygous PPARγ missense variants are present in as many as 1 in 500 people, though prospective functional classification of all possible missense variants in PPARγ suggests that many of these are benign and that gene-environment interactions are important (17, 41).

Some human evidence supports the notion that the degree of loss of PPARγ function correlates with the severity of lipodystrophy. A child harboring biallelic PPARG mutants, a frameshift mutation and a DBD mutation that were predicted to result in near-complete loss of PPARγ function, presented with a congenital generalized lipodystrophy phenotype (42). In contrast, the most common PPARγ variant, p.Pro12Ala (rs1801282, minor allele frequency 0.11), which is thought to only mildly modify PPARγ function, reduces the risk of developing type 2 diabetes without obviously causing a lipodystrophic phenotype (43).

In addition to the in vitro data referred to above, mouse studies strongly support observations that varying levels of PPARγ function produce a spectrum of phenotypes. Complete knockout of Pparγ is lethal for mice because of its requirement in placental and cardiac development (44). However, mice with embryon-
characterized by dark discoloration and velvety thickening of flexural skin, and children may have a progeroid-like appearance due to the lack of facial adipose tissue. Patients are essentially aleptinemic, and leptin replacement therapy is now a mainstay of therapy, as discussed below.

**Biallelic** \textit{AGPAT2} mutations associated with CGL are predicted to profoundly disrupt the protein product. Many are splice site mutations that result in a frameshift with premature stop codons or exon skipping (53). Only a few missense variants have been identified in patients with \textit{AGPAT2}-associated CGL, including p.Glu172Lys, which is thought to prevent the binding of substrate and catalytic activity (54). Functional studies have consistently demonstrated that mutants linked to CGL result in almost complete loss of \textit{AGPAT2} enzymatic activity (55).

\textit{AGPAT2} demonstrates tissue-selective expression in both visceral and subcutaneous adipose tissue, unlike \textit{PPARγ}, which is widely expressed (56). Homozygous loss-of-function variants appear to cause a failure of early adipogenesis due to several proposed interlinked mechanisms: perturbation of phospholipids, inhibition of PPARγ, and adipocyte apoptosis (57–59). There is a profound alteration of the lipidome, including reduced phosphatidylinositol and elevated lysophosphatidyl choline, in \textit{AGPAT2}-knockdown 3T3-L1 adipocytes (60), the result of which is reduced activity in the PI3K/AKT pathway and inhibition of \textit{Pparg} knockout (45), heterozygous \textit{Pparg} knockout, \textit{Pparg} hypomorphism (46), or adipose-specific \textit{Pparg} knockout all have a lipodystrophic phenotype (including insulin resistance and elevated triglycerides) (47). Several of these models also manifested abnormalities in blood pressure: hypotension in embryonal-only knockout and hypertension in P465L knockin mice (consistent with the human condition), though this model did not demonstrate insulin resistance or hypertriglycerideremia (48).

Therefore, impairment in the transcriptional control of adipogenesis results in a reproducible white adipose tissue–mediated partial lipodystrophy associated with all the characteristic features of the metabolic syndrome, the severity of which correlates, at least broadly, with residual PPARγ activity.

\textit{AGPAT2}. The most severe form of lipodystrophy is congenital generalized lipodystrophy (CGL), which is inherited in an autosomal recessive manner (49). Mutations in \textit{AGPAT2} (encoding 1-acylglycerol-3-phosphate O-acyltransferase 2) are responsible for a substantial proportion of these patients (50). \textit{AGPAT2} is a lysophosphatidic acid acyltransferase that plays a key role in the synthesis of triglycerides from glycerol-3-phosphate (51).

Affected patients present from infancy with an almost complete lack of adipose tissue, extreme insulin resistance, hypertriglycerideremia (potentially leading to pancreatitis), and severe hepatic steatosis (52). Many have acanthosis nigricans, a condition characterized by dark discoloration and velvety thickening of flexural skin, and children may have a progeroid-like appearance due to the lack of facial adipose tissue. Patients are essentially aleptinemic, and leptin replacement therapy is now a mainstay of therapy, as discussed below.

Biallelic \textit{AGPAT2} mutations associated with CGL are predicted to profoundly disrupt the protein product. Many are splice site mutations that result in a frameshift with premature stop codons or exon skipping (53). Only a few missense variants have been identified in patients with \textit{AGPAT2}-associated CGL, including p.Glu172Lys, which is thought to prevent the binding of substrate and catalytic activity (54). Functional studies have consistently demonstrated that mutants linked to CGL result in almost complete loss of \textit{AGPAT2} enzymatic activity (55).

\textit{AGPAT2} demonstrates tissue-selective expression in both visceral and subcutaneous adipose tissue, unlike \textit{AGPAT1}, which is widely expressed (56). Homozygous loss-of-function variants appear to cause a failure of early adipogenesis due to several proposed interlinked mechanisms: perturbation of phospholipids, inhibition of PPARγ, and adipocyte apoptosis (57–59). There is a profound alteration of the lipidome, including reduced phosphatidylinositol and elevated lysophosphatidyl choline, in \textit{AGPAT2}-knockdown 3T3-L1 adipocytes (60), the result of which is reduced activity in the PI3K/AKT pathway and inhibition
of PPARγ activity. The lack of AKT signaling results in adipocyte apoptosis, and though PPARγ overexpression may partially restore the adipogenic potential in AGPAT2-knockout cells, they still undergo apoptosis (61). These conclusions are supported by a lipodystrophic phenotype in Agpat2-null mice (62).

These findings highlight the devastating metabolic consequences of near-total fat loss due to a major impairment in the ability of adipocytes to synthesize triglyceride. This defect in neutral lipid synthesis is compounded by sustained hyperphagia due to severe leptin deficiency in CGL.

**PLIN1.** The perilipins are a group of proteins that were originally identified as highly abundant proteins covering the surface of lipid droplets (63–65). Since then they have been found to be critical for the regulation of lipolysis from lipid droplets (66–69); specifically, PLIN1 regulates the first two steps in triglyceride hydrolysis, namely those catalyzed by adipose tissue triglyceride lipase (ATGL) and hormone-sensitive lipase (HSL; encoded by Lipe), the major diglyceride lipase.

Gandotra et al. identified the first three families affected with heterozygous loss-of-function PLIN1 mutations, all of which were inherited in an autosomal dominant fashion (70). They presented with partial lipodystrophy, particularly manifesting a lack of subcutaneous lower limb and gluteofemoral fat. Biochemically, they had hypoadiponectinemia, hyperinsulinemia, NAFLD, and profound hypertriglyceridemia. Two different frameshift mutations were reported, both of which were shown to be expressed and to be targeted to the surface of lipid droplets (70). The mutant PLIN1 reported in these cohorts increased basal lipolysis in an in vitro model (67) by failing to effectively bind ABHD5, a key activator of ATGL (71–73). PLIN1 is almost exclusively expressed in white and brown adipocytes, where it is very specifically involved in stabilizing lipid droplets and in regulating lipolysis; thus the phenotype described in patients with PLIN1 mutations highlights the fact that a highly specific defect affecting energy storage in adipocytes is sufficient to produce almost all the features of the metabolic syndrome.

**CIDEC.** Cell death–inducing DFFA-like effector C (CIDEC; also known as the murine form, Fsp27) is another lipid droplet–associated protein that is expressed in white adipose tissue (74, 75), where it is required for the formation of large unilocular lipid droplets (76). Mice lacking Fsp27 uniformly manifest reduced fat mass with multilocular lipid droplets in all white adipocytes (77, 78), and overexpression of Fsp27/CIDEC in a range of cell types consistently increases lipid droplet size (79, 81–89). Many human cell types can contain lipid droplets, including myocytes, hepatocytes, and pancreatic islet cells. However, these lipid droplets always adopt a multilocular form, whereas the ability to form a single massive lipid droplet is a unique property of the white adipocyte (82). This high volume-to-surface-area ratio facilitates very precise regulation of lipolysis, which is clearly important in a cell type responsible for bulk storage (and release) of surplus energy as neutral lipid for the whole organism.

In 2009, a single patient was identified with a partial lipodystrophy phenotype caused by a homozygous nonsense mutation in CIDEC (83). Clinically, the patient had absent lower limb and gluteofemoral adipose tissue with reduced total body fat mass. The proband had poorly controlled diabetes mellitus with a propensity for ketoadiposis despite elevated C-peptide and negative anti-islet and anti–glutamic acid decarboxylase antibodies. She also had severe hypertriglyceridemia (resulting in acute pancreatitis), acanthosis nigricans, hepatic steatosis, and hypertension. Fat biopsy demonstrated a mixed population of white adipocytes with many, though not all, containing multilocular lipid droplets. This unusual phenotype was recapitulated in an adipocyte–specific Fsp27-knockout mouse (84), which similarly demonstrated multilocular white adipocytes, in addition to insulin resistance. When fed a chow diet, Fsp27-null mice are lean and insulin sensitive; however, when challenged over many weeks with a high-fat diet, or when crossed with obesity-prone ob/ob mice or mice lacking brown adipose tissue, these mice do manifest NAFLD and severe insulin resistance (78).

Though apparently a very rare condition in humans, these data further demonstrate that disruption of the ability of white adipocytes to form unilocular lipid droplets is sufficient to cause partial lipodystrophy and features of the metabolic syndrome.

**Other genetic lipodystrophies**

Several other human genetic lipodystrophies have been recognized, though exactly how these cause lipodystrophy is less clear. Biallelic loss-of-function mutations in BSCL2 (encoding seipin) on chromosome 11 are a major cause of CGL (52). Affected patients have almost complete absence of body fat from birth, severe insulin resistance, and hypertriglyceridemia (85). The syndrome is also associated with cardiomyopathy and intellectual disability. BSCL2 is clearly critical for the development and function of cultured white adipocytes (86, 87), and both whole-body and adipose-specific Bscl2-knockout mice manifest a lipodystrophic phenotype (88). Recent cryogenic electron microscopy–derived structural models suggest that both the *Drosophila* ortholog (89) and human seipin (90) oligomerize to form a ring-like structure in the ER membrane. These data are consistent with seipin’s proposed involvement in the early formation of lipid droplets from the ER, a model supported by a series of yeast (91) and other cell-based experiments (92, 93).

Heterozygous mutations in lamin A/C are probably the most common cause of monogenic partial lipodystrophy (94–96). Lamin A/C is a well-established component of the nuclear lamina network expressed in almost all cells. Different LMNA mutations have also been linked to cardiomyopathy and muscular dystrophy, and some patients with LMNA-associated partial lipodystrophy do also manifest variable degrees of cardiac and skeletal muscle impairment. As intermediate filaments, lamins clearly impact nuclear structure and transcriptional regulation of gene expression, but exactly why specific mutations are more strongly associated with particular phenotypes and why nuclear perturbation leads to partial lipodystrophy remain unclear (97, 98).

Finally, one specific variant (R707W) in mitofusin 2 (MFN2), the gene classically mutated in Charcot-Marie-Tooth type 2A, has been linked to a striking adipose overgrowth–lipodystrophy phenotype known as multiple symmetric lipomatosis (99). Patients with biallelic R707W mutations develop fat hyperplasia on their back and neck with lower limb lipodystrophy, NAFLD, insulin resistance, and peripheral neuropathy (100). A particularly remarkable aspect of this phenotype is very low leptin levels despite the fact that patients retain excess upper body fat (100, 101). Mitochondrial fusion–fission dynamics are essential for all metabolically active
tissues, but how this single variant confers an adipose phenotype is yet to be established (102).

As summarized in Tables 1 and 2, several additional genetic variants have been linked to specific forms of lipodystrophy. Further details related to all these disorders can be found in the references cited in Tables 1 and 2.

**Lipodystrophy and insulin resistance**

The central hallmark of the metabolic syndrome is insulin resistance, and, other than obesity itself, compelling arguments exist linking almost all the features of the metabolic syndrome to underlying insulin resistance (144). Insulin resistance is a consistent feature of lipodystrophy and reveals a number of specific insights:

---

**Table 1. The main congenital generalized and familial partial lipodystrophies with their involved genes and proposed pathogenic mechanisms**

<table>
<thead>
<tr>
<th>Gene and clinical syndrome</th>
<th>Pattern of inheritance</th>
<th>Clinical phenotype</th>
<th>Mechanism category</th>
<th>Gene product function</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Congenital generalized lipodystrophies (CGLs)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AGPAT2 (CGL1)</td>
<td>Autosomal recessive</td>
<td>Near-complete absence of adipose tissue from birth, severe IR, profound hypertriglyceridemia, NAFLD</td>
<td>Failure of triglyceride synthesis</td>
<td>Lysophosphatidic acid acyltransferase: synthesis of triglycerides from glycerol-3-phosphate</td>
<td>53, 57, 59, 60</td>
</tr>
<tr>
<td>BSCL2 (CGL2)</td>
<td>Autosomal recessive</td>
<td>As for CGL1, plus intellectual disability and cardiomyopathy</td>
<td>Lipid droplet dysfunction and/or impaired adipogenesis</td>
<td>ER-localized protein needed for lipid droplet formation and adipogenesis</td>
<td>87, 103–108</td>
</tr>
<tr>
<td>CAV1 (CGL3)</td>
<td>Autosomal recessive</td>
<td>Neonatal loss of adipose tissue, severe IR, dyslipidemia, pulmonary hypertension, short stature</td>
<td>Perturbed caveolar function</td>
<td>Key component of plasma membrane caveolae, which may participate in lipid uptake</td>
<td>109–112</td>
</tr>
<tr>
<td>PTRF (CGL4)</td>
<td>Autosomal recessive</td>
<td>Generalized loss of adipose tissue, hypertrophic cardiomyopathy, skeletal myopathy, less severe IR</td>
<td>Perturbed caveolar function</td>
<td>PTRF encodes cavin-1, which forms a protein complex needed for assembling, regulating, and stabilizing caveolae</td>
<td>113, 114</td>
</tr>
</tbody>
</table>

| **Familial partial lipodystrophies (FPLDs)** | | | | | |
| Polygenic (FPLD1, “Köbberling”) | Polygenic | Distal lipoatrophy, increased visceral adiposity, NAFLD, IR, low leptin and adiponectin | Various | Polygenic influences impairing adipogenesis and fat distribution | 115 |
| LMNA (FPLD2, “Dunnigan”) | Autosomal dominant | Loss of subcutaneous fat (particularly gluteofemoral) with face and neck sparing, NAFLD, IR, cardiomyopathy and/or muscular dystrophy in some | Nuclear envelope perturbation | Nuclear envelope protein that influences transcriptional regulation, but tissue-specific effects are poorly understood | 94, 96 |
| PPARC (FPLD3) | Autosomal dominant | Distal lipoatrophy with variable visceral adiposity, hypertension, (postprandial) hypertriglyceridemia, NAFLD, and PCOS | Defect in adipogenesis | Nuclear receptor central to transcriptional control of adipogenesis and mature adipocyte function | 26, 28, 39 |
| PLIN1 (FPLD4) | Autosomal dominant | Distal (particularly gluteofemoral) lipoatrophy, NAFLD, IR | Lipid droplet dysfunction | Lipid droplet protein that regulates triglyceride lipolysis | 66–68, 70 |
| CIDEC (FPLD5) | Autosomal recessive | Distal lipoatrophy with preserved neck and axillary fat, NAFLD, hypertriglyceridemia, pancreatitis, hypertension, microalbuminuria, multilocular adipocytes (note: single patient) | Lipid droplet dysfunction | Lipid droplet protein that is needed for the formation of large, unilocular lipid droplets | 79, 83, 116 |
| LIPE (FPLD6) | Autosomal recessive | Distal lipoatrophy, myopathy, dyslipidemia, NAFLD | Altered lipolysis | Encodes hormone-sensitive lipase, a key lipolytic enzyme | 117, 118 |
| AKT2 (unclassified) | Autosomal dominant | Distal lipoatrophy and IR | Defect in adipogenesis | AKT2 (protein kinase B) is a component of the insulin signaling pathway and is required for normal adipogenesis | 119 |
| ADRA2A (unclassified) | Autosomal dominant | Peripheral lipoatrophy with excess facial and neck adipose tissue, buffalo hump, IR, hypertension | Altered lipolysis | Adrenergic receptor normally involved in reducing adipocyte lipolysis | 120 |

The four recognized CGL syndromes result in extreme insulin resistance with almost complete loss of adipose, whereas FPLD is associated with peripheral (lower limb) adipose loss and substantial insulin resistance. In some cases the mechanism linking the gene product and lipodystrophy and adipose tissue dysfunction is unclear. ADRA2A, α2A-adrenergic receptor; AGPAT2, 1-acylglycerol-3-phosphate O-acyltransferase 2; AKT2, AKT serine/threonine kinase 2; BSCL2, Berardinelli-Seip congenital lipodystrophy 2; CAV1, caveolin 1; CGL, congenital generalized lipodystrophy; CIDEC, cell death–inducing DFFA-like effector C; FPLD, familial partial lipodystrophy; IR, insulin resistance; LIPE, hormone-sensitive lipase; LMNA, lamin A/C; NAFLD, nonalcoholic fatty liver disease; PCOS, polycystic ovary syndrome; PLIN1, perilipin 1; PPARC, peroxisome proliferator–activated receptor γ; PTRF, polymerase I and transcript release factor. |
Lipodystrophy is an associated feature in several complex genetic syndromes and other isolated genetic defects, the mechanism of which is unclear in most cases. Acquired lipodystrophy is presumed to be autoimmune in origin or may be related to treatment for HIV. BLM/RECQL3, Bloom syndrome; WRN, Werner syndrome; ZMPSTE24, ZMPSTE24 zinc metallopeptidase.
(a) Despite the range of different genetic and acquired causes of lipodystrophy, almost all “appreciable” (by which we mean at least partial in terms of extent) lipodystrophies are associated with insulin resistance. Exceptions that we are aware of include patients with FBN1 mutations, though in this setting, the “apparent lipodystrophy” is more likely to be secondary to reduced food intake. In all other instances, lipodystrophies are associated with very low or at least relatively low leptin levels, and thus a tendency to hyperphagia.

(b) The severity of insulin resistance is broadly proportional to the extent of fat loss or dysfunction. In other words, generalized lipodystrophy is typically associated with more severe metabolic manifestations than partial lipodystrophy. Furthermore, upper body fat loss is less prone to be associated with metabolic disease than gluteofemoral fat loss. This is best exemplified by cases of Barraquer-Simons acquired partial lipodystrophy, in which the fat loss proceeds in a cephalocaudal pattern: this entity is often associated with the presence of C3 nephritic factor and sometimes with renal glomerular disease, and insulin resistance is usually not a feature unless fat loss extends down to the gluteofemoral adipose depot and/or patients are otherwise obese (140).

Another intriguing form of partial lipodystrophy is that associated with dermatomyositis; in these cases, lipodystrophy most prominently affects subcutaneous depots, whereas visceral fat is often preserved (145). The patients frequently manifest advanced NAFLD and insulin resistance.

Finally, in this context, metabolic disease is also typically more severe in affected girls/women than in boys/men, presumably because under normal circumstances fat mass in a lean woman is roughly twice that in a lean man (146). Collectively, the two points above indicate that lack and/or dysfunction of white fat is consistently associated with insulin resistance and the metabolic syndrome, particularly when the defect in white fat is compounded by hyperphagia due to relative leptin deficiency (147, 148).

(c) NAFLD is a very consistent feature in insulin-resistant lipodystrophies, and is typically associated with metabolic dyslipidemia (high triglycerides and low HDL cholesterol). While there are limited data on liver histology in patients with lipodystrophy (149, 150), one study found that 40% of biopsied patients had bridging fibrosis or cirrhosis and 62% had definite steatohepatitis at a mean age of 29 years (38).

(d) Patients with lipodystrophy are prone to early-onset cardiovascular disease. In some ways, this appears to be as severe as the cardiovascular disease associated with heterozygous familial hypercholesterolemia, as we have had several women present with ischemic events well before the age of 50 years (151, 152).

(e) Circulating markers of cellular or mitochondrial stress (e.g., FGF21 and GDF15) are elevated in both obesity (153, 154) and lipodystrophy (155). Patel et al. recently showed that chronic energetic overload results in an increase in serum GDF15 and FGF21 in mice (156), and at least in the case of GDF15, this change may help to alleviate ongoing surplus energy intake.

However, this potentially “corrective” GDF15 signal is offset in lipodystrophic patients by relative or near-complete leptin deficiency, a key signal for the persistent hyperphagia observed in many patients with lipodystrophy. Unfortunately, hyperphagia compounds the relative deficiency of adipocyte energy storage capacity and is considered a major factor in the pathogenesis of metabolic disease in this disorder. Obese patients have elevated leptin levels, in keeping with their increased total fat mass (157), though it does not seem to suppress hunger, and therefore the term “leptin resistance” has been coined. In both lipodystrophy and obesity (158), the relative lack of leptin action contributes to ongoing surplus energy intake and insulin resistance, although it should be noted that leptin signaling at its receptor is actually increased in obesity and that a lack of response to additional exogenous leptin is complex and incompletely understood (159).

Adiponectin is an adipokine that paradoxically falls in obesity and insulin resistance, though the mechanisms underlying control of its release are unclear. Adiponectin levels are also low in lipodystrophy, and this is generally in proportion to the loss of adipose tissue (i.e., lower in CGL than in FPLD) and the severity of insulin resistance (160).

Insulin receptor signaling defects

“Insulin receptoropathies,” a term used to describe insulin-resistant states caused by a mutation or acquired defect in one of the proximal insulin signaling components (most commonly the insulin receptor [INSR] itself), represent another cluster of monogenic disorders associated with severe insulin resistance (161). Examination of the differences between patients with obesity-related metabolic syndrome, lipodystrophy, and insulin receptoropathies (Table 3) indicates that whereas lipodystrophy-associated and obesity-associated metabolic syndrome are strikingly concordant, there are several marked differences between the latter and insulin receptoropathies. In particular, NAFLD and dyslipidemia are typically not seen in insulin receptoropathies (162), and adiponectin levels tend to be high rather than low in these conditions (163).

Adipose inflammation

Histological assessment of adipose tissue from patients with the metabolic syndrome consistently demonstrates features of inflammation (164–166), the extent of which correlates with the severity of insulin resistance and NAFLD in humans (167). Inflammation appears to be more prominent in adipose tissue with higher lipolytic capacity (particularly visceral adipose); however, opinion remains divided on the extent to which macrophage infiltration is pathogenic in adipose dysfunction and/or insulin resistance (168). Obesity-associated insulin resistance is a state of chronic, systemic inflammation, as evidenced by elevated IL-6, high-sensitivity C-reactive protein, and GDF15, among other markers, but these derive from more than just adipose tissue. Nevertheless, adipose tissue macrophages certainly act as one source of inflammatory cytokines that contribute to the systemic inflammatory state, and their contribution appears to be ameliorated by weight loss (169).

There have been only a few studies examining the histology of adipose tissue in patients with inherited lipodystrophy. Patients with FPLD4 secondary to PLIN1 mutations had similar features of inflammation and fibrosis to those reported in obese people, whereas patients with CIDEC-associated lipodystrophy (83), MFN2-associated lipodystrophy (100), and LMNA mutations (170) did not demonstrate gross inflammation. Collectively, evidence from genetic lipodystrophies that almost always cause severe insulin resistance tends to suggest that adipose inflammation is a second “hit” rather than
the primary driver of adipose dysfunction and so, at least in our view, raises questions about the widespread interest in anti-inflammatory strategies for obesity-associated metabolic disease.

NAFLD is a very consistent feature of lipodystrophies that are severe enough to cause insulin resistance and other features of the metabolic syndrome. In this scenario, nonalcoholic steatohepatitis is very common and could conceivably be involved in causing hepatic insulin resistance. However, here too the liver pathology is very likely to occur secondary to adipose tissue dysfunction.

Evidence for subtle lipodystrophy in the general population

The striking overlap between lipodystrophy and more prevalent forms of the metabolic syndrome (Table 3) has long suggested that subtle forms of lipodystrophy may be relevant to the pathogenesis of metabolic syndrome and type 2 diabetes in particular (171–173). However, direct supportive evidence has been hard to come by, so it has remained a largely hypothetical premise.

In 2014, Scott et al. undertook a GWAS that used fasting insulin as a proxy for insulin resistance (174). Intriguingly, just over half the loci associated with a higher fasting insulin were also associated with higher triglycerides, lower HDL cholesterol, and a lower BMI and/or a reduction in gluteofemoral fat mass as measured by dual x-ray absorptiometry (DXA) scanning. Lotta et al. later performed a much larger GWAS focused on loci associated with a combination of BMI-adjusted insulin, higher triglycerides, and lower HDL cholesterol (175). This analysis identified 53 loci, which were replicated in a second cohort and shown to be significantly associated with gold-standard hyperinsulinemic-euglycemic clamp–based measures of insulin resistance. In a large human cohort in whom fat mass and distribution were documented with DXA scans, there was a significant association between higher insulin-resistant SNP scores and lower levels of glycid and leg fat mass (175). Interestingly, in this study, reduced expansion of gluteofemoral fat depot was also documented in response to weight gain (175). Importantly, this 53 SNP score was enriched in patients with FPLD1, which is in many ways an extreme form of apple-shaped fat distribution, implying that these common alleles contribute to both common insulin resistance and a specific form of partial lipodystrophy known as FPLD1 (Figure 3). This is also consistent with observations that there are a large number of patients with clinical features of FPLD1 (or FPLD2) with no known genetic diagnosis.

Waist/hip ratio (WHR) is a widely used noninvasive measure of adipose tissue distribution, and its relationship to diabetes and cardiovascular risk is well established (176, 177). Given that WHR is a ratio, it can be modified by changes in either the numerator or the denominator. However, visceral fat accumulation (i.e., an increase in the numerator) is usually assumed to be the driving factor behind the link between this index of fat distribution and insulin resistance. This notion is also supported by considerable scientific evidence (178–182). However, when Lotta et al. generated SNP risk scores for loci shown to be associated with a higher WHR, through a specific association with either a reduction in hip circumference (22 of a total of 202 loci) or an increase in waist circumference (36 of 202 loci), both scores were associated with cardiometabolic risk factors as well as an increase in the odds ratio of developing type 2 diabetes mellitus and coronary disease (183). Intriguingly, the odds ratio for the risk of type 2 diabetes was statistically significantly greater for the hip–specific risk score than the waist–specific score, whereas the odds ratios for cardiovascular disease were similar. Collectively these data are at least consistent with the notion that subtle partial lipodystrophy is a major factor in the pathogenesis of the metabolic syndrome in the general population (Figure 3). Put another way, people with an impaired capacity to increase hip fat mass in response to weight gain are more likely to develop insulin resistance and type 2 diabetes if they do increase their weight.

Shared treatment strategies for lipodystrophy and obesity

The implications of these observations are that therapeutic strategies in both lipodystrophy and obesity-related metabolic syndrome should aim to minimize adipocyte overload. This could be achieved by increasing adipocyte number/function or by reducing the energetic load on adipose tissue.

Increasing fat mass is a highly effective method for treating the metabolic syndrome in mice. Evidence from animal models has demonstrated the profound benefits associated with adipose transplant in severely lipodystrophic mice (184, 185). But, aside from being cosmetically unappealing, fat transplantation would also be technically challenging in humans. However, thiazolidinediones, which selectively activate PPARγ, very effectively improve insulin sensitivity in the clinical setting, primarily by increasing subcutaneous fat mass (186).
Conclusion

Inherited lipodystrophies are a complex group of conditions, all of which ultimately impair adipose tissue function and particularly its capacity to efficiently store surplus energy. The metabolic sequelae of lipodystrophy are remarkably similar to those associated with obesity, and compelling human genetic evidence now suggests that this similarity reflects adipocyte overload in both settings. Thus the goal of treatment in both states is to alleviate the energetic burden on adipocytes by inducing negative energy balance and/or weight loss.

Acknowledgments

JPM is supported by a Wellcome Trust Fellowship (216329/Z/19/Z). DBS is supported by the Wellcome Trust (WT 107064), the Medical Research Council (MRC) Metabolic Diseases Unit (MRC_MC_UU_12012/2), and the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre and NIHR Rare Disease Translational Research Collaboration.

Address correspondence to: David B. Savage, Metabolic Research Laboratories, Level 4, Institute of Metabolic Science, Box 289, Addenbrooke’s Hospital, Cambridge, United Kingdom CB2 0QQ. Phone: 44.1223.767923; Email: dbs23@cam.ac.uk.

REVIEW SERIES: MECHANISMS UNDERLYING THE METABOLIC SYNDROME

40. Fernández-Galíeira M, Tapia P, Cautivo K, Morrell E, Cortés VA. AGPAT2 deficiency impairs adipogenic differentiation in primary cultured


